Trial Profile
A retrospective study to investigate efficacy of switching to intravitreal aflibercept treatment in patients with polypoidal choroidal vasculopathy who were refractory to ranibizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 09 Dec 2015 New trial record